Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Increased psychological symptom burden in patients with pancreatic cancer: A population-based cohort study: Increased psychological symptom burden in patients with pancreatic cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Pain in pancreatic ductal adenocarcinoma: A multidisciplinary, International guideline for optimized management

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. How do people with rheumatoid arthritis experience participation in a smoking cessation trial: a qualitative study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Acinar cystic transformation of the pancreas: Report of a case and a review of the literature

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND/OBJECTIVE: To investigate the psychological symptom burden in patients with pancreatic cancer.

METHODS: We used Danish population-based registries to identify 10,793 pancreatic cancer patients and 109,238 age and gender matched cancer-free comparison persons between the years 2000-2016. The cohorts were followed up to five years for first prescription for antidepressants, anxiolytics or hypnotics as proxies for the psychological symptom burden of depression, anxiety or insomnia. Cumulated incidence proportions were analysed using the pseudo-value approach and hazards were estimated with Cox regression models adjusted for potential confounders.

RESULTS: The highest HR for first antidepressant use was seen in the first six months after diagnosis (HR 8.73 (95% CI: 7.57; 10.06)). Within the first two years the overall estimated cumulated probability of 12.9% (95% CI: 12%; 13.8%) in pancreatic cancer patients, and 4.6% (95% CI: 4.5%; 4.8%) in comparisons, and 20.4% and 31.4% patients received first prescription of anxiolytics or hypnotics, respectively. We found no difference in HRs of first antidepressant by gender, year of diagnosis, cohabitation, education or comorbidity in the patient cohort, however younger age (<59 years) was associated with depression.

CONCLUSIONS: Pancreatic cancer patients are at risk for first antidepressant, anxiolytic and hypnotic use up to five years after diagnosis. Patients younger than 59 years, newly diagnosed with advanced pancreatic cancer, and not treated with surgery were more likely to have first antidepressant use. The study calls for interventions to reduce the psychological burden in advanced pancreatic cancer patients which may improve quality of life and survival.

OriginalsprogEngelsk
TidsskriftPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Vol/bind20
Udgave nummer3
Sider (fra-til)511-521
Antal sider11
ISSN1424-3903
DOI
StatusUdgivet - apr. 2020

Bibliografisk note

Copyright © 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.

ID: 59211499